| The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, JJ Luke, ... Science 359 (6371), 104-108, 2018 | 2455 | 2018 |
| Targeted agents and immunotherapies: optimizing outcomes in melanoma JJ Luke, KT Flaherty, A Ribas, GV Long Nature reviews Clinical oncology 14 (8), 463-482, 2017 | 1166 | 2017 |
| Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer C Massard, MS Gordon, S Sharma, S Rafii, ZA Wainberg, J Luke, ... Journal of Clinical Oncology 34 (26), 3119, 2016 | 894 | 2016 |
| Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA GR Oxnard, CP Paweletz, Y Kuang, SL Mach, A O'Connell, MM Messineo, ... Clinical cancer research 20 (6), 1698-1705, 2014 | 848 | 2014 |
| Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin FS Hodi, CL Corless, A Giobbie-Hurder, JA Fletcher, M Zhu, ... Journal of clinical oncology 31 (26), 3182, 2013 | 676 | 2013 |
| Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy L Heinzerling, PA Ott, FS Hodi, AN Husain, A Tajmir-Riahi, H Tawbi, ... Journal for immunotherapy of cancer 4, 1-11, 2016 | 521 | 2016 |
| Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, ... Journal of Clinical Oncology 36 (16), 1611, 2018 | 515 | 2018 |
| WNT/β-catenin pathway activation correlates with immune exclusion across human cancers JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski Clinical Cancer Research 25 (10), 3074-3083, 2019 | 511 | 2019 |
| Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma S Spranger, JJ Luke, R Bao, Y Zha, KM Hernandez, Y Li, AP Gajewski, ... Proceedings of the National Academy of Sciences 113 (48), E7759-E7768, 2016 | 379 | 2016 |
| T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection JA Trujillo, RF Sweis, R Bao, JJ Luke Cancer immunology research 6 (9), 990-1000, 2018 | 356 | 2018 |
| Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis BW Labadie, R Bao, JJ Luke Clinical Cancer Research 25 (5), 1462-1471, 2019 | 314 | 2019 |
| Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037) TC Mitchell, O Hamid, DC Smith, TM Bauer, JS Wasser, AJ Olszanski, ... Journal of Clinical Oncology 36 (32), 3223, 2018 | 305 | 2018 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 299 | 2022 |
| The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma AN Shoushtari, RR Munhoz, D Kuk, PA Ott, DB Johnson, KK Tsai, ... Cancer 122 (21), 3354-3362, 2016 | 276 | 2016 |
| Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study L Min, FS Hodi, A Giobbie-Hurder, PA Ott, JJ Luke, H Donahue, M Davis, ... Clinical Cancer Research 21 (4), 749-755, 2015 | 269 | 2015 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 265 | 2020 |
| Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020 | 241 | 2020 |
| STING pathway agonism as a cancer therapeutic BA Flood, EF Higgs, S Li, JJ Luke, TF Gajewski Immunological reviews 290 (1), 24-38, 2019 | 230 | 2019 |
| STING agonists as cancer therapeutics A Amouzegar, M Chelvanambi, JN Filderman, WJ Storkus, JJ Luke Cancers 13 (11), 2695, 2021 | 213 | 2021 |
| Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana‐Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan … JJ Luke, MK Callahan, MA Postow, E Romano, N Ramaiya, M Bluth, ... Cancer 119 (20), 3687-3695, 2013 | 200 | 2013 |
Riyue BaoAssociate Professor, UPitt Medicine; Co-Director Bioinformatics, UPMC Hillman Cancer CenterZweryfikowany adres z pitt.edu
